ZIMLAB Q2 : NET LOSS WIDENS 382.4% TO ₹2.1 CR (YOY), NARROWS FROM ₹4 CR (QOQ)

Revenue up 18.9% at ₹105.4 Cr (YOY), up 12.0% (QOQ). Ebitda down 1.2% at ₹7.7 Cr (YOY); margins 7.3% v 8.8% (YOY), 3.7% (QOQ). H1 FY27 revenue up 24.4% at ₹199.6 Cr; Ebitda down 17.6% at ₹11.1 Cr, margins 5.6% v 8.4% (YOY). Caution: ~₹180 Mn spent over 15 months on EU GMP remediation; one-time costs not expected to fully recur in H2.

Zim Laboratories Ltd

Open attachment

← Back to feed